subject: Candidiasis - Drug Pipeline Analysis And Market Forecasts To 2016---aarkstore Enterprise Market [print this page] Candidiasis - Drug Pipeline Analysis and Market Forecasts to 2016
Summary
Candidiasis - Drug Pipeline Analysis and Market Forecasts to 2016, provides an essential source of information and analysis on the global candidiasis market. The report identifies the key trends shaping and driving the global candidiasis market. The report also provides insights on the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights on the pipeline products within the global candidiasis sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis bys team of industry experts.
Forecasts the global candidiasis market to reach $2,386m by 2016. This moderate growth will primarily be supported by an increase in the disease incidence rate and the launch of two promising pipeline molecules during the forecast period. The growth of the candidiasis market during the forecast period will not be much higher than the rate at which it grew between 2001 and 2009. This is primarily attributed to two reasons. First, the candidiasis market is dominated by generic products which generate less revenue per unit volume sold. Second, the pipeline of the candidiasis market is weak with a small number of molecules across different stages of development. However, the continued uptake of the currently marketed products and the launch of some of the late-stage pipeline molecules will sustain market growth during the forecast period.
Scope
The scope of the report includes:
- Annualized global candidiasis market revenues data from 2001 to 2009, forecast for seven years to 2016.
- Geographies covered in this report are the United States (the US), the United Kingdom (the UK), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include monoclonal antibodies, cytochrome inhibitors, combination therapies, aminio acid sequences and antimicrobial peptides, selective immune response amplifiers, vaccines and protein synthesis inhibitors.
- Analysis of the current and future market competition in the global candidiasis market. The key market players covered Neutec Pharma PLC (a wholly owned subsidiary of Novartis AG), Novartis AG, Demegen, Inc. and Basilea Pharmaceutica Ltd.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future candidiasis market.
